资讯内容 Content
[ACC2011]预防房颤卒中的抗栓和抗凝治疗进展——Michael D. Ezekowitz 教授专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。
International Circulation: A number of researchs have suggested that new anticoagulation agents, rivaroxaban, apixaban, dabigatran, can prevent stroke in atrial fibrillation patients. Can you compare and contrast those new anticoagulation agents?
《国际循环》:一些研究表示,在心房颤动患者中,新型抗凝药物利伐沙班、apixaban 和达比加群可预防卒中。请您谈谈这些新型抗凝剂的差异?
Dr. Ezekowitz: First of all, it is very difficult and probably hazardous to compare one drug with another. The only way that you can make a legitimate comparison is to do a head-to-head comparison between these various agents in a single clinical trial. When you compare these trials without a head-to-head comparison, it lends itself to criticism. Hav
上一页 [1] [2] [3] [4]